Studies have reported strong evidence that suggests YKL-40, α-HB, soluble CD36, leptin, resistin, IL-18, RBP4, and chemerin could be new biomarkers for the pathogenesis of insulin resistance and endothelial dysfunction in T2DM patients. This evidence concerns the gene LEP and endothelial dysfunction.